About Dr. Xu Jianmin
Dr. Xu Jianmin (许剑民) is one of China's most distinguished colorectal surgeons and the Director of the Department of Colorectal Surgery at Zhongshan Hospital, affiliated with Fudan University. He holds the title of Chief Physician and Professor and is nationally recognized as a leading authority on colorectal cancer surgery, laparoscopic and robotic colorectal surgery, and multidisciplinary colorectal cancer management.
Over a career spanning more than three decades, Dr. Xu has established himself as one of China's foremost colorectal cancer surgeons, with a particular focus on rectal cancer surgery, sphincter-preserving techniques, and conversion therapy for initially unresectable colorectal cancer. His contributions to China's national colorectal cancer surgical guidelines and his leadership of landmark multicenter trials have shaped colorectal cancer management across the country.
International patients with colorectal cancer — whether seeking primary surgical treatment, a second opinion on surgical planning, or access to conversion therapy protocols for advanced disease — consistently identify Dr. Xu as one of China's top colorectal surgeons.
Professional Positions and Affiliations
- Director, Department of Colorectal Surgery, Zhongshan Hospital, Fudan University
- Chairman, Colorectal Cancer Committee, Chinese Anti-Cancer Association (CACA)
- Vice Chairman, Chinese Society of Colorectal Surgery
- Editorial Board Member: Annals of Surgery, Diseases of the Colon and Rectum, Colorectal Disease
- Fellow, American Society of Colon and Rectal Surgeons (ASCRS)
- Fellow, European Society of Coloproctology (ESCP)
Specialties and Clinical Expertise
- Rectal Cancer Surgery — total mesorectal excision (TME) by open, laparoscopic, and robotic approaches; intersphincteric resection (ISR) for ultra-low rectal cancer with sphincter preservation; abdominoperineal resection (APR) with extended resection for locally advanced disease; transanal TME (TaTME)
- Colon Cancer Surgery — complete mesocolic excision (CME) with central vascular ligation; laparoscopic right and left hemicolectomy; robotic-assisted colectomy
- Conversion Therapy for Unresectable Colorectal Cancer — chemotherapy plus targeted therapy (bevacizumab, cetuximab) or immunotherapy (PD-1 inhibitors for MSI-H tumors) to convert initially unresectable liver metastases or locally advanced primary tumors to resectable; one of China's leading centers for this approach
- Colorectal Liver Metastases — simultaneous resection of primary tumor and liver metastases; staged resection; coordination with hepatobiliary surgery and interventional radiology
- Locally Advanced Rectal Cancer — neoadjuvant chemoradiation followed by TME; watch-and-wait strategy for complete clinical responders; total neoadjuvant therapy (TNT) protocols
- Hereditary Colorectal Cancer — Lynch syndrome, familial adenomatous polyposis (FAP); prophylactic colectomy and surveillance
- Inflammatory Bowel Disease Surgery — restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis; Crohn's disease surgery
- Transanal Minimally Invasive Surgery (TAMIS) — local excision of early rectal tumors and large polyps
Academic and Research Contributions
Dr. Xu Jianmin has published over 200 peer-reviewed papers in leading international colorectal surgery and oncology journals, with a particular focus on conversion therapy for unresectable colorectal cancer, sphincter-preserving surgery for low rectal cancer, and the optimization of neoadjuvant therapy protocols. His landmark research on conversion therapy — demonstrating that a significant proportion of patients with initially unresectable colorectal liver metastases can achieve resectability with intensive chemotherapy plus targeted therapy — has been widely cited and has influenced national and international guidelines.
He chairs the Colorectal Cancer Committee of the Chinese Anti-Cancer Association and has been a lead author on China's national colorectal cancer surgical guidelines. He is a regular invited speaker at ASCRS, ESCP, and the United European Gastroenterology Week (UEGW).
Why International Patients Choose Dr. Xu Jianmin
- China's leading colorectal cancer surgeon — Chairman of CACA Colorectal Cancer Committee and national guideline author
- Conversion therapy pioneer — transforming unresectable colorectal cancer into resectable disease
- Sphincter-preserving expertise — ISR and TaTME for ultra-low rectal cancer avoiding permanent colostomy
- ASCRS and ESCP Fellow — internationally credentialed and aligned with global colorectal surgery standards
- Watch-and-wait program — for complete responders after neoadjuvant therapy, avoiding surgery entirely
- English-language support available through CMCS concierge coordination
Practical Information for International Patients
- Hospital: Zhongshan Hospital, 180 Fenglin Road, Xuhui District, Shanghai
- Appointment Lead Time: 2″4 weeks; urgent cases expedited through CMCS
- Languages: Mandarin Chinese; English interpretation provided by CMCS
- Pre-consultation: Overseas CT, MRI, colonoscopy, and pathology reports reviewed remotely through CMCS
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking colorectal surgery with Dr. Xu Jianmin at Zhongshan Hospital. Our services include priority appointment booking, medical record and imaging translation, remote pre-consultation review, on-site interpretation, accommodation coordination, insurance liaison, and post-surgical follow-up with your home country oncologist or surgeon.
📧 Contact us: contract@medicalsh.com
🌐 medicalsh.com
0 comments